Physician profile
Alan Sutter
NPI 1295584548
$1,220.28
in general payments reported to CMS, 2019-2025
11 companies · $792 in 2025
The $792 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $428 · 2025: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,220.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $283.40 | 2024-2025 | Xdemvy |
| Abbvie INC. | $246.55 | 2024-2025 | |
| Alcon Vision LLC | $227.95 | 2024-2025 | Total30, Precision7, Marlo |
| Bausch & Lomb Americas INC. | $212.67 | 2024-2025 | Infuse Multifocal, Infuse, Vyzulta |
| Apellis Pharmaceuticals, INC. | $100.99 | 2025 | Syfovre |
| Sun Pharmaceutical Industries INC. | $43.85 | 2024-2025 | |
| Amgen INC. | $27.68 | 2025 | Tepezza |
| Oyster Point Pharma, INC. | $21.25 | 2025 | Ryzumvi, Tyrvaya |
| Dompe US, INC. | $19.66 | 2025 | Oxervate |
| Harrow Eye, LLC | $19.27 | 2024 | Ilevro |
| Rxsight INC | $17.01 | 2025 | Light Adjustable Lens (Lal), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Sutter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.